Although the analysis of the primary MCL samples indicate that the mechanisms responsible for araC resistance in vivo are more complex than those observed in vitro, it must be emphasized that downregulation of gene and protein DCK was indeed confirmed in a substantial part of the patients’ post-treatment samples (Table 3, Figure 7A,B). The gene discussed is DCK; the disease is mantle cell lymphoma.